ERBB2 and gastric cancer: If future phase II/III trials are implemented under clinical trial designs that allow sufficient verification of the potential of c-Met expression as a biomarker to aid the identification of cases in which rilotumumab is effective, a field of c-Met-positive gastric cancer may be established, similarly to that of HER2-positive gastric cancer.